AUPH · Aurinia Pharmaceuticals Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on AUPH. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About AUPH · Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Live Quote
BUY (score +7) · 12-1 mom 91.9% · RSI 73.8 · above_both · 0.0% from high
Targets blend Wall Street consensus (7 analysts: low $15.00 / mean $17.00 / high $21.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Score falls well below the 60 threshold for asymmetric plays due to a narrow insider cluster (only 1 buyer), lack of institutional confirmation, and missing quantifiable mispricing/quality metrics. Dilution risk is negated by an active $300M buyback program, but the setup lacks the breadth of catalysts and structural support required to clear the bar.
Score falls well below the 60 threshold for asymmetric plays due to a narrow insider cluster (only 1 buyer), lack of institutional confirmation, and missing quantifiable mispricing/quality metrics. Dilution risk is negated by an active $300M buyback program, but the setup lacks the breadth of catalysts and structural support required to clear the bar.
Aurinia is a profitable biotech commercializing LUPKYNIS (voclosporin) for lupus nephritis. The investigation was triggered by Kevin Tang's Form 4 open-market purchase cluster in Feb-Mar 2026 (~900,000 shares at $13.90–$14.38 via his LP funds), followed by the March C-suite takeover (Tang named CEO, Hearne CFO, Cole COO). That cluster is verified P-code insider buying — the most significant signal on the stock. The company just closed the Kezar Life Sciences acquisition (May 8, 2026) for $41M, adding pipeline assets and triggering a CVR structure with potential milestone payments tied to zetomipzomib development or licensing. Q1 2026 earnings beat by 27%; forward P/E of ~14x is modest relative to biotech peers; FCF yield is strong at ~6%. The May 18, 2026 Form 4 grants (PSU awards with price-target vesting conditions) from new executives are equity compensation, not cash purchases — they signal alignment but aren't the open-market buy cluster that triggered this investigation. Options IV of 47–67% supports covered-call or strangle strategies near earnings.